ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Stock
1 member of Congress disclosed 1 trade in ARWR since 2023: 0 purchases and 1 sale, most recently Daniel Goldman (sale, Jan 31, 2023). 6 of the hedge funds AlphaScala tracks reported ARWR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $38.22M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which members of Congress traded ARROWHEAD PHARMACEUTICALS, INC. (ARWR)?
Most recent: Daniel Goldman (sale, Jan 31, 2023); records start Jan 31, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-01-31 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all ARWR political trades →Which hedge funds own ARWR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 469K | $38.22M | -55% |
| D.E. Shaw David Shaw | 432K | $35.18M | -64% |
| Millennium Management Israel Englander | 329K | $26.84M | NEW |
| Marshall Wace | 305K | $24.86M | +70% |
| Hussman Investment Trust John Hussman | 21K | $1.71M | NEW |
| Blackstone | 5K | $420.5K | -60% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ARROWHEAD PHARMACEUTICALS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 18, 26 | Olukotun Adeoye Y | Director | SELL | 2.0K | $174K |
| Aug 18, 26 | Perry Michael S | Director | SELL | 11.6K | $1.0M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →ARWR price chart
Powered by TradingViewWhat does ARROWHEAD PHARMACEUTICALS, INC. do?
Arrowhead Pharmaceuticals is a biotechnology company focused on developing innovative medicines for intractable diseases. The company specializes in RNA interference (RNAi) therapeutics, a cutting-edge approach to treating genetic and metabolic disorders by targeting disease-causing proteins at the molecular level. Its pipeline includes several clinical-stage candidates addressing significant unmet medical needs, such as Plozasiran for cardiovascular disease, Zodasiran for lipid disorders, and ARO-INHBE for metabolic dysfunction-associated liver disease. The company also develops investigational therapies targeting conditions including chronic kidney disease, obesity, and neurodegenerative diseases. Arrowhead operates in the growing biotechnology sector, where it competes alongside other drug developers pursuing advanced therapeutic approaches. Founded in 2003 and headquartered in the United States, Arrowhead represents the emerging class of precision medicine companies leveraging molecular biology to address diseases that traditional pharmaceuticals have struggled to treat effectively.